AMI Research Updates Analyst Coverage On NeoGenomics

Key Largo, Fla. – December 2, 2009 -- AMI Research, (http://www.amistockreports.com) a division of Hawk Associates, today announced that it has published updated stock research coverage on NeoGenomics, Inc. (OTCBB: NGNM) based on its third quarter 2009 financial earnings results.

AMI Research provides a comprehensive look at NeoGenomics’ third quarter key statistics, the company’s conference call, a financial outlook and a conclusion. The complete 15-page report is available to download for free at the AMI Research website, http://www.amistockreports.com.

About NeoGenomics
NeoGenomics Inc., (http://www.neogenomics.org) is a CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. Staffed with specially trained hematopathologists and cytogenetic professionals, NeoGenomics Laboratories offers testing in cancer genetics, flow cytometry, immunohistochemistry and molecular diagnostics through its network of regional laboratories. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.

About AMI Research
AMI Research is a leading provider of issuer-paid stock research coverage and a division of Hawk Associates Inc. AMI Research offers high quality and credible fundamental analysis of promising small companies that do not have traditional Wall Street analyst coverage. Please visit http://www.amistockreports.com.

AMI Research abides by the Best Practice Guidelines Governing Analyst and Corporate Issuer Relationships, developed by the CFA Institute in conjunction with the National Investor Relations Institute (NIRI).  The cost of a one-year continuing research program is $30,000 prepaid for four research reports. AMI does not accept payment of fees in company shares. All AMI Research and Hawk Associates personnel are prohibited from trading in securities of covered companies. Neither the analyst’s compensation nor the compensation received by AMI Research is in any way related to the specific ratings or views contained in this research report.